Details of the Drug Reposition

General Information of This Drug (ID: DM652O6)

Drug Name
Livoletide   DM652O6
Synonyms
AZP-531; AZP 531; UNII-9VHD7J6363; 9VHD7J6363; 1088543-62-7; 3-((3S,6S,9S,12S,15S,18S,21S,26aS)-6-((1H-imidazol-5-yl)methyl)-9,18-bis(3-amino-3-oxopropyl)-12-(3-guanidinopropyl)-21-(hydroxymethyl)-15-isopropyl-1,4,7,10,13,16,19,22-octaoxohexacosahydropyrrolo[1,2-a][1,4,7,10,13,16,19,22]octaazacyclotetracosin-3-yl)propanoic acid; AZP531; CHEMBL2029605; GTPL10884; Cyclo(des-acyl ghrelin(6-13)); DB15188; Q27896244; 3-((3S,6S,9S,12S,15S,18S,21S,24S)-6,15-Bis(3-amino-3-oxo-propyl)-12-(3-guanidinopropyl)-3-(hydroxymethyl)-18-(1H-imidazol-5-ylmethyl)-9-isopropyl-2,5,8,11,14,17,20,23-octaoxo-1,4,7,10,13,16,19,22-octazabicyclo(22.3.0)heptacosan-21-yl)propanoic acid; Cyclo(L-arginyl-L-valyl-L-glutaminyl-L-seryl-L-prolyl-L-alpha-glutamyl-L-histidyl-L-glutaminyl)
Drug Type
Peptide
Structure
3D MOL is unavailable 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 2/3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Prader-Willi syndrome DISYWMLU LD90.3 Phase 2/3 [1]
Hyperphagia DIS9KBZX MG43.9 Phase 2/3 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03790865) Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome (ZEPHYR). U.S. National Institutes of Health.